AIM: To investigate the usefulness of anti-ulcer drugs for the prevention and treatment of low-dose aspirin-induced peptic ulcer. METHODS: Upper gastrointestinal endoscopy was performed in 68 patients receivingdaily low-dose aspirin (81 or 100 mg/day). The endoscopic findings were classified according to the Lanza score, and the scores were compared between groups categorized according to the concomitant use of anti-ulcer drugs and the types of drugs used. In another study, 31 hemorrhagic peptic ulcer patients who had been receiving low-dose aspirin were enrolled. The patients were randomly classified into the proton pump inhibitor (PPI)-treated group and the H2 receptor antagonist (H2RA)-treated group. The administration of low-dose aspirin was continued concomitantly, and endoscopic examinations were performed 8 wk later. RESULTS: The Lanza scores (mean +/- SD) of the gastro-mucosal lesions were 1.0 +/- 1.9 and 1.9 +/- 2.3 in 8 and 16 patients receiving prevention therapy with a PPI and an H2RA, respectively. Both scores were significantly smaller than the scores in 34 patients who were not receiving prevention therapy (4.7 +/- 1.0) and in 10 patients receiving cytoprotective anti-ulcer drugs (4.3 +/- 1.6). In the prospective study, 18 and 13 patients received a PPI and an H2RA, respectively. Endoscopic examinations revealed that the tissue in the region of the gastro-mucosal lesions had reverted to normal in all patients in the PPI-treated group and in 12 patients (92%) in the H2RA-treated group; no significant differences were observed between the groups. CONCLUSION:H2RA therapy was effective for both the prevention and treatment of low-dose aspirin-induced peptic ulcer, similar to the effects of PPIs, while cytoprotective anti-ulcer drugs were ineffective in preventing ulceration.
RCT Entities:
AIM: To investigate the usefulness of anti-ulcer drugs for the prevention and treatment of low-dose aspirin-induced peptic ulcer. METHODS: Upper gastrointestinal endoscopy was performed in 68 patients receiving daily low-dose aspirin (81 or 100 mg/day). The endoscopic findings were classified according to the Lanza score, and the scores were compared between groups categorized according to the concomitant use of anti-ulcer drugs and the types of drugs used. In another study, 31 hemorrhagic peptic ulcerpatients who had been receiving low-dose aspirin were enrolled. The patients were randomly classified into the proton pump inhibitor (PPI)-treated group and the H2 receptor antagonist (H2RA)-treated group. The administration of low-dose aspirin was continued concomitantly, and endoscopic examinations were performed 8 wk later. RESULTS: The Lanza scores (mean +/- SD) of the gastro-mucosal lesions were 1.0 +/- 1.9 and 1.9 +/- 2.3 in 8 and 16 patients receiving prevention therapy with a PPI and an H2RA, respectively. Both scores were significantly smaller than the scores in 34 patients who were not receiving prevention therapy (4.7 +/- 1.0) and in 10 patients receiving cytoprotective anti-ulcer drugs (4.3 +/- 1.6). In the prospective study, 18 and 13 patients received a PPI and an H2RA, respectively. Endoscopic examinations revealed that the tissue in the region of the gastro-mucosal lesions had reverted to normal in all patients in the PPI-treated group and in 12 patients (92%) in the H2RA-treated group; no significant differences were observed between the groups. CONCLUSION: H2RA therapy was effective for both the prevention and treatment of low-dose aspirin-induced peptic ulcer, similar to the effects of PPIs, while cytoprotective anti-ulcer drugs were ineffective in preventing ulceration.
Authors: F K Chan; S C Chung; B Y Suen; Y T Lee; W K Leung; V K Leung; J C Wu; J Y Lau; Y Hui; M S Lai; H L Chan; J J Sung Journal: N Engl J Med Date: 2001-03-29 Impact factor: 91.245
Authors: H Tahir; K Sumii; K Haruma; A Tari; N Uemura; H Shimizu; M Sumioka; Y Inaba; T Kumamoto; Y Matsumoto Journal: Hiroshima J Med Sci Date: 1984-06
Authors: C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans Journal: N Engl J Med Date: 1998-03-12 Impact factor: 91.245
Authors: S Nakashima; S Arai; Y Mizuno; K Yoshino; S Ando; Y Nakamura; K Sugawara; M Koike; E Saito; M Naito; M Nakao; H Ito; K Hamaoka; F Rai; Y Asakura; M Akamatu; K Fujimori; M Inao; Y Imai; S Ota; K Fujiwara; M Shiibashi Journal: Aliment Pharmacol Ther Date: 2005-06 Impact factor: 8.171
Authors: Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: A S Taha; N Hudson; C J Hawkey; A J Swannell; P N Trye; J Cottrell; S G Mann; T J Simon; R D Sturrock; R I Russell Journal: N Engl J Med Date: 1996-05-30 Impact factor: 91.245
Authors: Chen Mo; Gang Sun; Ming-Liang Lu; Li Zhang; Yan-Zhi Wang; Xi Sun; Yun-Sheng Yang Journal: World J Gastroenterol Date: 2015-05-07 Impact factor: 5.742